HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection (CTN289)

November 10, 2022 updated by: Ottawa Hospital Research Institute

Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (ECF/TAF) Switch Followed by Ledipasvir-Sofosbuvir HCV Therapy in HIV-HCV Co-Infection: A CIHR Canadian HIV Trials Network-Gilead Pilot Trial Proposal

This is an prospective open label pilot study conducted over 32 weeks.

A total of 25 eligible participants who are infected with HCV and HIV will be recruited from 2 Canadian HIV Trials Network (CTN) sites (Ottawa Hospital Research Institute and McGill University Health Centre)

This study is investigating the effectiveness of a combination of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide Single Tablet Regimen (E/C/F/TAF STR) for HIV treatment and Harvoni for HCV treatment.

This study will assess the effect that the study drug has on the metabolism of sugar, the changes in fat in the bloodstream, and other metabolic changes. Metabolism is the process your body uses to get or make energy from the food you eat.

This study may provide information on the impact of liver fibrosis (scarring of liver tissues) on metabolic changes before, during and after HCV antiviral therapy.

Drug-drug interactions (DDI) between E/C/F/TAF and LPV-SOF have been well evaluated and no clinically significant interactions have been identified.

A switch to E/C/F/TAF in the context of LPV-SOF HCV antiviral treatment preparation may be particularly beneficial because of its:

  1. favorable side effect profile
  2. once daily STR formulation
  3. known DDI profile with LPV-SOF
  4. neutral effect on liver fibrosis
  5. improved kidney and bone safety profile with the use of TAF

Conduct of this study is justified as it:

  1. Assesses a minimal pill count and dosing frequency strategy of co-treatment of HIV and HCV using well tolerated medications with an excellent safety profile and known DDI profile.
  2. Provides additional safety data for TAF in the HIV-HCV co-infected population.
  3. Quantifies adherence and identifies obstacles to full adherence in this population. There is a paucity of data related to DAA adherence in licensing studies.
  4. Provides real-world safety and efficacy data to support the public funding for LPV-SOF DAA therapy in HIV-HCV co-infected populations.
  5. Provides preliminary data on the immunologic and metabolic consequences of HCV clearance in HIV-HCV co-infection
  6. As a pilot study, the information gathered will inform the feasibility of future clinical trials evaluating novel treatment strategies for HIV-HCV co-infected patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The availability of interferon (IFN)-free HCV Direct Acting Antiviral (DAA) antiviral therapy such as Ledipasvir-Sofosbuvir (LPV-SOF) allows for broad provision of treatment for populations living with HIV-HCV. Co-infected persons frequently have competing co-morbidities and are at risk for progressive liver disease which makes adherence and combined management of HIV and HCV challenging. Simple, safe, well tolerated regimens with few drug-drug interactions could be highly beneficial in ensuring success of HCV therapy in this population. With this is mind, the optimal management of antiretroviral therapy prior to initiating LPV-SOF treatment remains unclear.

E/C/F/TAF [elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide fumarate (TAF)] will be assessed in this study because it is formulated as a single tablet which facilitates adherence by once daily dosing and reduced pill count. It is established to be affective at achieving and maintaining HIV virologic suppression. The safety profile of this HIV regimen is excellent. The E/C/F/TAF formulation assessed in this study will contain TAF. This formulation has been evaluated in HIV-infected populations and found to be of equivalent HIV antiviral activity and to have improved impact on renal and bone metabolism [ref: David Wohl, Anton Pozniak, Melanie Thompson, Edwin DeJesus, Daniel Podzamczer, Jean-Michel Molina, Gordon Crofoot, Christian Callebaut, Hal Martin, Scott McCallister. Tenofovir Alafenamide (TAF) in a Single-Tablet Regimen in Initial HIV-1 Therapy. Conference on Retroviruses and Opportunistic Infections. 113LB. February 23-26, 2015, Seattle, Washington.]. There is minimal safety data in HIV-HCV co-infection.

Drug-drug interactions (DDI) between HIV antiretrovirals and HCV antivirals remain a key obstacle to the safe and effective delivery. The DDI between E/C/F/TAF and LPV-SOF have been well evaluated and no clinically significant interactions have been identified.

A switch to E/C/F/TAF in the context of LPV-SOF HCV antiviral treatment preparation may be particularly beneficial because of its:

  1. favorable side effect profile
  2. once daily STR formulation
  3. known DDI profile with LPV-SOF
  4. neutral effect on liver fibrosis
  5. improved kidney and bone safety profile with the use of TAF

Conduct of this study is justified as it:

  1. Assesses a minimal pill count and dosing frequency strategy of co-treatment of HIV and HCV using well tolerated medications with an excellent safety profile and known DDI profile (Complera followed by LPV-SOF). Polypharmacy in the co-infected population remains a significant challenge to therapeutic success.
  2. Provides additional safety data for TAF in the HIV-HCV co-infected population.
  3. Quantifies adherence and identifies obstacles to full adherence in this population. There is a paucity of data related to DAA adherence in licensing studies.
  4. Provides real-world safety and efficacy data to support the public funding for LPV-SOF DAA therapy in HIV-HCV co-infected populations.
  5. Provides preliminary data on the immunologic and metabolic consequences of HCV clearance in HIV-HCV co-infection
  6. As a pilot study, the information gathered will inform the feasibility of future clinical trials evaluating novel treatment strategies for HIV-HCV co-infected patients.

Study Type

Interventional

Enrollment (Actual)

25

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Ottawa, Ontario, Canada
        • The Ottawa Hospital, General Campus
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • The Research Institute of the McGill University Health Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • HIV infected (ELISA with western blot confirmation)
  • HCV RNA positive for minimum of 6 months / Genotype 1
  • Prescribed cART that may include any Department of Health and Human Services (DHHS) recommended or alternative regimens, which the treating physician considers, is appropriate for their patient. (We anticipate that approximately 60% will be on HIV protease inhibitor-based regimens).
  • HIV RNA BLLQ for minimum of 3 months
  • Stage 3 or 4 fibrosis
  • No evidence of liver decompensation defined as past or current ascites, bleeding varices or hepatic encephalopathy. Prior interferon, ribavirin and/or HCV protease inhibitor exposure will be allowed with the exception of cirrhotic with a past history of null response to interferon-based therapy.
  • Ability to remain adherent to medications and study protocol as per investigator opinion
  • For female subjects, not pregnant, planning or suspected to be pregnant or breast-feeding
  • Willing to use acceptable methods of birth control, as defined in protocol
  • Active substance use and/or mental health issues will not be exclusionary assuming other criteria are met. This inclusion will be restricted to those stably housed and engaged in harm reduction strategies. Our intent is to evaluate study participants who are representative of our clinical population and consider 'difficult to cure' compared to populations already evaluated in licensing studies

Exclusion Criteria:

  • Concomitant use of drugs with contraindication drug interactions with E/C/F/TAF of SOF-LDV
  • History of HIV integrase inhibitors or NRTI resistance mutations
  • Platelets <50 x10^9/L

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active Treatment
E/C/F/TAF Ledipasvir-Sofosbuvir/TAF
Drug: E/C/F/TAF;
Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
Other Names:
  • Genvoya
  • emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate
Drug: Ledipasvir-Sofosbuvir
Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
Other Names:
  • Harvoni

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of approached patients who agreed to switch from their current Antiretroviral (ARV) regimen and be screened for this study
Time Frame: 52 weeks
Number of patients
52 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of subjects achieving SVR12
Time Frame: 24 weeks
HCV RNA at 12 weeks post HCV treatment completion
24 weeks
Proportion of subjects maintaining undetectable HIV RNA levels
Time Frame: 32 weeks
HIV RNA below detection throughout study period
32 weeks
Proportion of subjects initiating HCV antiviral therapy
Time Frame: 4 weeks
Number of participants
4 weeks
Proportion of subjects discontinuing study medications due to adverse events
Time Frame: 32 weeks
Liver enzyme abnormalities
32 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measures of fibrosis will be assessed over the duration of the study.
Time Frame: 32 weeks
Serial Fibroscan assessment at screening, week 12 of Ledipasvir/Sofosbuvir (LDV/SOF) dosing, and 12 weeks after HCV treatment.
32 weeks
Measures of serial cellular immune will be assessed over the duration of the study.
Time Frame: 32 weeks
CD4 cell counts at Baseline, week 4, week 12, and 12 weeks post treatment
32 weeks
Measures of serial cytokine immune function will be assessed over the duration of the study.
Time Frame: 32 weeks
Blood will be drawn at each time point for measurement of adipokines (e.g. adiponectin, retinal binding protein 4, interleukin 6, resistin, leptin, visfatin and omentin). (Blood volume: 20 ml).
32 weeks
Measures of metabolic function (cholesterol) will be assessed over the duration of the study
Time Frame: 32 weeks
Serial measurement of cholesterol at Baseline, week 4, week 12, and 12 weeks post treatment
32 weeks
Measures of metabolic function (glucose) will be assessed over the duration of the study
Time Frame: 32 weeks
Serial measurement of glucose at Baseline, week 4, week 12, and 12 weeks post treatment
32 weeks
Measures of metabolic function (insulin) will be assessed over the duration of the study
Time Frame: 32 weeks
Serial measurement of insulin at Baseline, week 4, week 12, and 12 weeks post treatment
32 weeks
Measures of metabolic function (lipokine) will be assessed over the duration of the study
Time Frame: 32 weeks
Serial measurement of lipokine at Baseline, week 4, week 12, and 12 weeks post treatment
32 weeks
Patient-focused outcome - Quality of life measure will be evaluated
Time Frame: 32 weeks
EuroQol 5-Dimensional (EQ-5D) questionnaire completed at weeks -4, Baseline, 4, 12 and 12 weeks post treatment to allow for assessment of quality-of-life through quality-adjusted life year (QALY) calculation
32 weeks
Patient-Focused Outcome - Physical Activity will be evaluated
Time Frame: 32 weeks
International Physical Activity Questionnaire Short-Form (IPAQ-sf) completed at baseline, week 4 and 12 to quantify total physical activity over the past 7 days reported as metabolic equivalent of task (MET) minutes per week across 4 domains: leisure, domestic, work, and transportation-related activities. IPAQ-sf classifies a total combined weekly physical activity score represented as high, moderate, or low activity.
32 weeks
Patient-Focused Outcome - Dietary status will be evaluated
Time Frame: 32 weeks
Block 2005 Food Frequency Questionnaire (FFQ) completed at baseline, week 12 and 12 weeks post treatment to assess dietary intake.
32 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ottawa Hospital Research Institute

Collaborators

Gilead Sciences
CIHR Canadian HIV Trials Network

Investigators

  • Principal Investigator: Curtis Cooper, MD, FRCPC, The Ottawa Hospital; Ottawa Hospital Research Institute
  • Principal Investigator: Marina Klein, MD, McGill University Health Centre/Research Institute of the McGill University Health Centre

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2016

Primary Completion (Actual)

January 1, 2018

Study Completion (Actual)

June 1, 2018

Study Registration Dates

First Submitted

October 21, 2015

First Submitted That Met QC Criteria

January 18, 2016

First Posted (Estimate)

January 21, 2016

Study Record Updates

Last Update Posted (Actual)

November 14, 2022

Last Update Submitted That Met QC Criteria

November 10, 2022

Last Verified

March 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20150881-01H

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatitis C, Chronic

Clinical Trials on E/C/F/TAF;

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe